nach oben

Cancer Chemotherapy and Pharmacology

Erschienen in:

01.02.2012 | Original Article

An all-oral combination of metronomic cyclophosphamide plus capecitabine in patients with anthracycline- and taxane-pretreated metastatic breast cancer: a phase II study

verfasst von: Zhonghua Wang, Jingsong Lu, Shiangjiin Leaw, Xiaonan Hong, Jialei Wang, Zhimin Shao, Xichun Hu

Erschienen in: Cancer Chemotherapy and Pharmacology | Ausgabe 2/2012

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Oral administration of cyclophosphamide (CTX) and capecitabine may have a greater potential for treatment of metastatic breast cancer (MBC) due to anti-angiogenesis resulting from the metronomic dosage and upregulation of thymidine phosphorylase by CTX. The purpose of this phase II study was to evaluate the efficacy and safety profile of an all-oral combination of metronomic CTX plus capecitabine for women with anthracycline- and taxane-pretreated MBC.

Method

In this prospective single-center, open-label, phase II trial, patients with measurable disease received oral metronomic CTX 65 mg/m² daily on days 1–14 plus capecitabine 1,000 mg/m² twice daily on days 1–14. The treatment was repeated every 3 weeks, and continued until disease progression, unacceptable toxicity or withdrawal of informed consent. The primary endpoint of the study was time to progression (TTP).

Results

A total of 68 patients were enrolled and received 537 cycles of chemotherapy with a median of 8 cycles (range: 1–30 cycles) per patient. Sixty-six patients were evaluated for efficacy with all patients for toxicity. With a median follow-up time of 26 months, the median time to progression was 5.2 months (95% CI, 4.2–6.2 months), and the median overall survival was 16.9 months. The overall response rate was 30.3% (95% CI, 20–43%). Clinical benefit rate was 53.0% (95% CI, 38–62%). The doublet was well tolerable, with anorexia (7.5%), the only grade 3/4 adverse events occurring in more than 5% of patients. Grade 3 hand–foot syndrome was 4.4%.

Conclusion

The all-oral combination of metronomic CTX plus capecitabine is an effective and convenient and well-tolerated regimen for MBC. (ClinicalTrials.gov number, NCT00589901).

Perez EA (2009) Impact, mechanisms, and novel chemotherapy strategies for overcoming resistance to anthracyclines and taxanes in metastatic breast cancer. Breast Cancer Res Treat 114:195–201PubMedCrossRef

Giordano SH, Buzdar AU, Smith TL et al (2004) Is breast cancer survival improving? Cancer 100:44–52PubMedCrossRef

Engelsman E, Klijn JC, Rubens RD et al (1991) “Classical” CMF versus a 3-weekly intravenous CMF schedule in postmenopausal patients with advanced breast cancer. An EORTC Breast Cancer Co-operative Group Phase III Trial (10808). Eur J Cancer 27:966–970PubMedCrossRef

Blum JL, Jones SE, Buzdar AU et al (1999) Multicenter phase II study of capecitabine in paclitaxel-refractory metastatic breast cancer. J Clin Oncol 17:485–493PubMed

Blum JL, Dieras V, Lo Russo PM et al (2001) Multicenter, phase II study of capecitabine in taxane-pretreated metastatic breast carcinoma patients. Cancer 92:1759–1768PubMedCrossRef

Reichardt P, Von Minckwitz G, Thuss-Patience PC et al (2003) Multicenter phase II study of oral capecitabine (Xeloda) in patients with metastatic breast cancer relapsing after treatment with a taxane-containing therapy. Ann Oncol 14:1227–1233PubMedCrossRef

Fumoleau P, Largillier R, Clippe C et al (2004) Multicentre, phase II study evaluating capecitabine monotherapy in patients with anthracycline- and taxane-pretreated metastatic breast cancer. Eur J Cancer 40:536–542PubMedCrossRef

Wist EA, Sommer HH, Ostenstad B et al (2004) Oral capecitabine in anthracycline- and taxane-pretreated advanced/metastatic breast cancer. Acta Oncol 43:186–189PubMedCrossRef

Thomas ES, Gomez HL, Li RK et al (2007) Ixabepilone plus capecitabine for metastatic breast cancer progressing after anthracycline and taxane treatment. J Clin Oncol 25:5210–5217PubMedCrossRef

10.

Estévez LG, Batista N, Sánchez-Rovira P et al (2008) A phase II study of capecitabine and vinorelbine in patients with metastatic breast cancer pretreated with anthracyclines and taxanes. Clin Breast Cancer 8:149–154PubMedCrossRef

11.

Orphanos G, Alexopoulos A, Malliou S et al (2010) A phase II trial of the combination of vinorelbine and capecitabine as second-line treatment in metastatic breast cancer previously treated with taxanes and/or anthracyclines. J Cancer Res Clin Oncol 136:115–121PubMedCrossRef

12.

Ahn JH, Kim SB, Kim TW et al (2004) Capecitabine and vinorelbine in patients with metastatic breast cancer previously treated with anthracycline and taxane. J Korean Med Sci 19:547–553PubMedCrossRef

13.

Jones A, O’Brien M, Sommer H et al (2010) Phase II study of oral vinorelbine in combination with capecitabine as second line chemotherapy in metastatic breast cancer patients previously treated with anthracyclines and taxanes. Cancer Chemother Pharmacol 65:755–763PubMedCrossRef

14.

Andres R, Mayordomo JI, Lara R et al (2005) Gemcitabine/capecitabine in patients with metastatic breast cancer pretreated with anthracyclines and taxanes. Clin Breast Cancer 6:158–162PubMedCrossRef

15.

Benekli M, Yildiz R, Uner A et al (2007) Gemcitabine plus capecitabine combination in metastatic breast cancer patients previously treated with anthracyclines and taxanes. Oncology 72:308–313PubMedCrossRef

16.

Malmström A, Hansen J, Malmberg L et al (2010) Gemcitabine and capecitabine in combination for advanced anthracycline and taxane pre-treated breast cancer patients: a phase II study. Acta Oncol 49:35–41PubMedCrossRef

17.

Maisano R, Caristi N, Mare M et al (2007) Mitomycin C plus capecitabine (mixe) in anthracycline- and taxane-pretreated metastatic breast cancer. A multicenter phase II study. Anticancer Res 27:2871–2875PubMed

18.

Massacesi C, La Cesa A, Marcucci F et al (2006) Capecitabine and mitomycin C is an effective combination for anthracycline- and taxane-resistant metastatic breast cancer. Oncology 70:294–300PubMedCrossRef

19.

Oksuzoglu B, Abali H, Hayran M et al (2008) Capecitabine and cisplatin combination is an active and well-tolerated doublet in the treatment of metastatic breast carcinoma patients pretreated with anthracycline and taxanes. Chemotherapy 54:352–356PubMedCrossRef

20.

Donadio M, Ardine M, Berruti A et al (2005) Weekly cisplatin plus capecitabine in metastatic breast cancer patients heavily pretreated with both anthracycline and taxanes. Oncology 69:408–413PubMedCrossRef

21.

Polyzos A, Gogas H, Markopoulos C et al (2009) Salvage chemotherapy with oxaliplatin and capecitabine for breast cancer patients pretreated with anthracyclines and taxanes. Anticancer Res 29:2851–2856PubMed

22.

Schmid P, Kühnhardt D, Kiewe P et al (2008) A phase I/II study of bortezomib and capecitabine in patients with metastatic breast cancer previously treated with taxanes and/or anthracyclines. Ann Oncol 19:871–876PubMedCrossRef

23.

Schaller G, Fuchs I, Gonsch T et al (2007) Phase II study of capecitabine plus trastuzumab in human epidermal growth factor receptor 2 overexpressing metastatic breast cancer pretreated with anthracyclines or taxanes. J Clin Oncol 25:3246–3250PubMedCrossRef

24.

Ishida T, Kiba T, Takeda M et al (2009) Phase II study of capecitabine and trastuzumab combination chemotherapy in patients with HER2 overexpressing metastatic breast cancers resistant to both anthracyclines and taxanes. Cancer Chemother Pharmacol 64:361–369PubMedCrossRef

25.

Bottini A, Generali D, Brizzi MP et al (2006) Randomized phase II trial of letrozole and letrozole plus low-dose metronomic oral cyclophosphamide as primary systemic treatment in elderly breast cancer patients. J Clin Oncol 24:3623–3628PubMedCrossRef

26.

Colleoni M, Orlando L, Sanna G et al (2006) Metronomic low-dose oral cyclophosphamide and methotrexate plus or minus thalidomide in metastatic breast cancer: antitumor activity and biological effects. Ann Oncol 17:232–238PubMedCrossRef

27.

Loven D, Be’ery E, Yerushalmi R et al (2008) Daily low-dose/continuous capecitabine combined with neo-adjuvant irradiation reduces VEGF and PDGF-BB levels in rectal carcinoma patients. Acta Oncol 47:104–109PubMedCrossRef

28.

Sawada N, Ishikawa T, Fukase Y et al (1998) Induction of thymidine phosphorylase activity and enhancement of capecitabine efficacy by taxol/taxotere in human cancer xenografts. Clin Cancer Res 4:1013–1019PubMed

29.

Endo M, Shinbori N, Fukase Y et al (1999) Induction of thymidine phosphorylase expression and enhancement of efficacy of capecitabine or 5’-deoxy-5-fluorouridine by cyclophosphamide in mammary tumor models. Int J Cancer 83:127–134PubMedCrossRef

30.

O’Shaughnessy J, Miles D, Vukelja S et al (2002) Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results. J Clin Oncol 20:2812–2823PubMedCrossRef

31.

Lueck H, Minckwitz GV, Bois AD et al. (2006) Epirubicin/paclitaxel (EP) vs. capecitabine/paclitaxel (XP) in first-line metastatic breast cancer (MBC): a prospective, randomized multicentre phase III study of the AGO breast cancer study group. J Clin Oncol 24:18 s

32.

Ohno S, Mitsuyama S, Tamura K et al (2007) Dosage of capecitabine and cyclophosphamide combination therapy in patients with metastatic breast cancer. Anticancer Res 27:1009–1013PubMed

33.

Hennessy BT, Gauthier AM, Michaud LB et al (2005) Lower dose capecitabine has a more favorable therapeutic index in metastatic breast cancer. Ann Oncol 16:1289–1296PubMedCrossRef

34.

Liu G, Franssen E, Fitch MI et al (1997) Patient preferences for oral versus intravenous palliative chemotherapy. J Clin Oncol 15:110–115PubMed

35.

Geyer CE, Forster J, Lindquist D et al (2006) Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med 355:2733–2743PubMedCrossRef

36.

Miller KD, Chap LI, Holmes FA et al (2005) Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer. J Clin Oncol 23:792–799PubMedCrossRef

37.

von Minckwitz G, du Bois A, Schmidt M et al (2009) Trastuzumab beyond progression in human epidermal growth factor receptor 2-positive advanced breast cancer: a german breast group 26/breast international group 03–05 study. J Clin Oncol 27:1999–2006CrossRef

38.

Robert NJ, Dieras V, Glaspy J et al (2011) RIBBON-1: randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab for first-line treatment of human epidermal growth factor receptor 2-negative, locally recurrent or metastatic breast cancer. J Clin Oncol 29:1252–1260PubMedCrossRef

39.

Brufsky A, Bondarenko IN, Smirnov V et al (2009) RIBBON-2: a randomized, double-blind, placebo-controlled, phase III trialevaluating the efficacy and safety of bevacizumab in combination with chemotherapy for second-line treatment of HER2-negative metastatic breast cancer. Cancer Res 69(24 Supplement):42CrossRef

40.

Tanaka M, Takamatsu Y, Anan K et al (2010) Oral combination chemotherapy with capecitabine and cyclophosphamide in patients with metastatic breast cancer: a phase II study. Anticancer Drugs 21:453–458PubMedCrossRef

41.

Tong DK, Cheng CW, Ching Chan S et al (2005) Phase II study of an ‘all-oral’ regimen of capecitabine, idarubicin and cyclophosphamide for metastatic breast cancer—safety, efficacy and quality of life. Oncology 68:520–525PubMedCrossRef

42.

Schott AF, Lew D, Barlow WE et al (2010) Simple oral therapy with capecitabine (CAPE) and cyclophosphamide (CPA) for metastatic breast cancer (MBC). J Clin Oncol 28:15s

43.

Haller DG, Cassidy J, Clarke S et al (2006) Tolerability of fluoropyrimidines appears to differ by region. J Clin Oncol 24:18sCrossRef

44.

Bonadonna G, Brusamolino E, Valagussa P et al (1976) Combination chemotherapy as an adjuvant treatment in operable breast cancer. N Engl J Med 294:405–410PubMedCrossRef

45.

Levine MN, Bramwell VH, Pritchard KI et al (1998) Randomized trial of intensive cyclophosphamide, epirubicin, and fluorouracil chemotherapy compared with cyclophosphamide, methotrexate, and fluorouracil in premenopausal women with node-positive breast cancer. National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 16:2651–2658PubMed

Titel: An all-oral combination of metronomic cyclophosphamide plus capecitabine in patients with anthracycline- and taxane-pretreated metastatic breast cancer: a phase II study
verfasst von: Zhonghua Wang
Jingsong Lu
Shiangjiin Leaw
Xiaonan Hong
Jialei Wang
Zhimin Shao
Xichun Hu
Publikationsdatum: 01.02.2012
Verlag: Springer-Verlag
Erschienen in: Cancer Chemotherapy and Pharmacology / Ausgabe 2/2012
Print ISSN: 0344-5704
Elektronische ISSN: 1432-0843
DOI: https://doi.org/10.1007/s00280-011-1728-3

Neu im Fachgebiet Onkologie

24.04.2024 | DGIM 2024 | Nachrichten

Springer Medizin

An all-oral combination of metronomic cyclophosphamide plus capecitabine in patients with anthracycline- and taxane-pretreated metastatic breast cancer: a phase II study

Abstract

Purpose

Method

Results

Conclusion

Neu im Fachgebiet Onkologie

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Krebspatienten impfen: Was? Wen? Und wann nicht?

Müde im Alter? Auch an die Nebenniere denken

Update Onkologie

Springer Medizin

Abstract

Purpose

Method

Results

Conclusion

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2012

Imatinib mesylate in thymic epithelial malignancies

A phase I study of 5-azacytidine and erlotinib in advanced solid tumor malignancies

Effect of trabectedin on the QT interval in patients with advanced solid tumor malignancies

Phase I dose escalation study of KOS-1584, a novel epothilone, in patients with advanced solid tumors

Phase I study of the synthetic triterpenoid, 2-cyano-3, 12-dioxoolean-1, 9-dien-28-oic acid (CDDO), in advanced solid tumors

Docetaxel plus gemcitabine in combination with capecitabine as treatment for inoperable pancreatic cancer: a phase II study

Neu im Fachgebiet Onkologie

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Krebspatienten impfen: Was? Wen? Und wann nicht?

Müde im Alter? Auch an die Nebenniere denken

Update Onkologie